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Dendritic cells (DCs) in mucosal surfaces are early
targets for human immunodeficiency virus-1 (HIV-1).
DCs mount rapid and robust immune responses
upon pathogen encounter. However, immune re-
sponse in the early events of HIV-1 transmission
appears limited, suggesting that HIV-1 evade early
immune control byDCs.We report that HIV-1 induces
a rapid shutdown of autophagy and immunoamphi-
somes in DCs. HIV-1 envelope activated themamma-
lian target of rapamycin pathway in DCs, leading to
autophagy exhaustion. HIV-1-induced inhibition of
autophagy in DC increased cell-associated HIV-1
and transfer of HIV-1 infection to CD4+ T cells. HIV-
1-mediated downregulation of autophagy in DCs
impaired innate and adaptive immune responses.
Immunoamphisomes in DCs engulf incoming patho-
gens and appear to amplify pathogen degradation
as well as Toll-like receptor responses and antigen
presentation. The findings that HIV-1 downregulates
autophagy and impedes immune functions of DCs
represent a pathogenesis mechanism that can be
pharmacologically countered with therapeutic and
prophylactic implications.
INTRODUCTION
Dendritic cells (DCs) are sentinels of the immune system
because of their privileged location at mucosal sites and of their
faculty to capture and present antigens to other immune cells
such as Ag-specific T cells (Iwasaki, 2007; Trombetta and
Mellman, 2005). DC-mediated immune responses during the
early events of Simian immunodeficiency virus (SIV) and human
immunodeficiency virus-1 (HIV-1) infection occur rapidly but are
insufficient to control subsequent propagation of the virus654 Immunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc.(Davenport et al., 2004; Li et al., 2009b; Reynolds et al., 2005; re-
viewed in Pope and Haase, 2003).
Sexual transmission, via mucosal tissues, is by far the most
common route of HIV-1 infection. DCs present in mucosal
surfaces are likely to be early reservoir targets for the virus
(reviewed in Piguet and Steinman, 2007; Wu and KewalRamani,
2006). HIV-1 has evolved strategies to evade, at least in part, the
first line of defense of the immune system in mucosal tissues.
HIV-1 degradation occurs early upon entry in DCs (Garcia
et al., 2005; Moris et al., 2004; Turville et al., 2004), but
5%–10% of initial viral input evades destruction and remains
in a tetraspanin-rich compartment, at least in part, connected
to the DC surface (Cavrois et al., 2007; Garcia et al., 2008; Yu
et al., 2008). Upon DC-T cell contact, HIV-1 rapidly polarizes to
the DC-T cell infectious synapse (Arrighi et al., 2004; McDonald
et al., 2003) via a trafficking route that might share similarities to
the exosome release pathway (Izquierdo-Useros et al., 2009;
Wiley and Gummuluru, 2006). The inability of DC to fully degrade
HIV-1, upon viral entry, is paralleled with a relative incapacity of
DCs tomature, with the exception of infection by very high doses
of virus (Harman et al., 2006); Granelli-Piperno et al., 2004;
Hodges et al., 2007; Patterson et al., 2005; as reviewed in Piguet
and Steinman, 2007).
DCs are able to process and present HIV-derived antigens
to established CD4+ and CD8+ T cell clones in vitro. (Jones
et al., 2007; Moris et al., 2004; Moris et al., 2006; Sabado
et al., 2007). However, HIV-1-infected DCs exhibit a limited
capacity to mature and to induce appropriate adaptive immune
responses (Granelli-Piperno et al., 2004; Kawamura et al.,
2003; Macatonia et al., 1990). The dysfunction of DCs could
contribute to early suppression of immune control of HIV and
SIV in mucosal tissues.
Autophagy, a specialized lysosomal degradation pathway, is
a cellular self-digestion process involved in protein and organ-
elle degradation (Klionsky, 2005; Levine and Kroemer, 2008).
Dysregulation of autophagy is associated with cancer, neuro-
degenerative disorders, and aging because of its involvement
in cell survival and general cellular homeostasis and function
(Levine and Kroemer, 2008; Mizushima et al., 2008). More
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defense mechanism against a range of intracellular microbes
including pathogens such as Mycobacterium tuberculosis or
herpes simplex virus-1 (HSV-1) (Gutierrez et al., 2004; Orve-
dahl et al., 2007). Autophagy regulates innate and adaptive
immune responses against intracellular pathogens (Deretic,
2005; Levine and Deretic, 2007; Virgin and Levine, 2009).
There is now growing evidence that autophagic organelles
called autophagosomes are able to engulf cytosolic compo-
nents and allow this material to be delivered to the lumen
of endosomal compartments, thus feeding MHC-II protein
complexes with antigens (Schmid et al., 2007) and perhaps
enhancing late-stage MHC-I antigen loading (English et al.,
2009). This phenomenon, referred to as endogenous antigen
presentation when self-antigens are in question, extends to
foreign cytosolic or cytoplasmic antigens produced by viruses
(Paludan et al., 2005). The underlying process of autophagic
capture and delivery of cytosolic components to antigen-pre-
senting compartments extends to cytosolic pathogen associ-
ated molecular patterns and their delivery to endosomal
pattern recognition receptors and has been collectively termed
autophagic topological inversion (Deretic, 2009). Given the
variety of ways that autophagy contributes to elimination of
intracellular microbes (Deretic and Levine, 2009), it is not
unexpected that intracellular and extracellular pathogens have
evolved strategies to modulate autophagy (Deretic and Levine,
2009).
In the case of HIV-1, the relationship between autophagy and
its effects on immune responses has not been explored. Auto-
phagic processes have been implicated in bystander T cell
death, induced by interaction of the HIV-1 Env associated on
the infected cell with CXCR4 in the contacting noninfected
CD4+ T cell, thus potentially amplifying CD4+ T cell depletion
(Denizot et al., 2008; Espert et al., 2006). There have been reports
describing autophagy inhibition in myeloid, lymphoid, and neu-
ronal cells upon HIV-1 or SIV infection (Alirezaei et al., 2008;
Zhou and Spector, 2008), although autophagy has been impli-
cated in resulting in higher viral yields in other cell types (Brass
et al., 2008; Kyei et al., 2009).
In this study, we found that HIV-1 infection impacts autophagy
in DCs. We observed that upon HIV-1 capture, the amount of
autophagosome-associated protein LC-3 was dramatically
downregulated after a few hours. Disappearance of autophago-
somal proteins in DCs was virus dose and time course depen-
dent. In DCs, we uncovered that HIV-1 Env induced a signaling
program leading to activation of mTOR and S6K, negative regu-
lators of autophagy. Upon inhibition of autophagosomal proteins
by RNA interference or drugs in DCs, we observed that the
amount of cell-associated virus was increased and that viral
transfer from DCs to CD4+ T cells was enhanced. Treatment
with rapamycin, a well-known mTOR inhibitor and autophagy
inducer, lead to a reduction in HIV-1 content in DCs and
a decrease in transfer of HIV-1 infection to T cells. Furthermore,
we show that HIV-1-exposed DCs were poorly responsive to
Toll-like receptor (TLR) agonists given that autophagy is required
in DCs for optimal TLR signaling. Finally, inhibition of autophagy
in DCs led to a decrease of MHC-II-dependent HIV-1 antigen
presentation to HIV-specific CD4+ T cell clones. These studies
highlight the presence of immunoamphisomes in DCs thatenhance HIV degradation upon capture and amplify innate and
adaptive immune responses.
In conclusion, we unravel a mechanism of immune escape
developed by HIV-1. The presented data show that HIV-1 can
counteract an autophagosome-mediated degradation in DCs
via mTOR pathway activation, leading to enhanced virus transfer
to T cells and resulting in impaired activation of both innate and
adaptive immune responses.
RESULTS
HIV-1 Inhibits Autophagy in DCs
Pathogen engulfment within autophagosomes can restrict path-
ogen invasion. Autophagosomes are characterized by mem-
brane incorporation of lipidated LC3 protein. We first evaluated
whether HIV-1 had an influence on autophagosomes in DC look-
ing at LC3+ puncta in cells upon HIV-1 capture.
Confocal analysis of immature monocyte-derived DCs (iDCs)
exposed for 20 hr with wild-type HIV-1 showed 60%
(p = 0.0216) less LC3+ puncta compared to nonexposed DC (NI)
(Figure 1A). In contrast, LPS-treated mature DCs (mDCs) had
a 3-fold increase in LC3+ puncta compared to nontreated iDCs
(data not shown). In side-by-side comparisons of cells, the
diminishment of LC3 signal was pronounced in HIV-1-containing
iDCs revealed by cytoplasmic Gag (data not shown). To extend
our analysis to primary blood-derived myeloid DCs (MyDCs),
we treated purified MyDC with HIV-1 and observed, as for
monocyte-derived DCs, a decrease in LC3+ puncta (Figure 1B).
Autophagosomes are mainly characterized by the membrane
incorporation of a phosphatidylethanolamine-lipidated form of
LC3 (LC3-II) upon modification of cytosolic LC3 (LC3-I). The lipid
modification of LC3 alters its electrophoretic mobility and thus
allows monitoring conversion of LC3-I to LC3-II.
Time-course experiments of HIV-1-mediated decrease in
LC3-II were performed with constant viral input (200 ng p24/
105 cells). A decrease in LC3-II could be detected as early as
1 hr after viral exposure and was more pronounced at 10 hr
(up to 62% downregulation) (Figure 1C). In contrast, cytosolic
LC3 (LC3-I) remained unaffected at these time points (Figure 1C).
Interestingly, decrease of autophagosomal LC3 upon 20 hr
HIV-1 exposure was also observed in monocyte-derived macro-
phages (MDMs) but not in primary CD4+ T cells (Figure S1 avail-
able online). Hence, we observed by immunoblotting (Figure S1)
up to a 60% decrease of LC3-II in iDCs exposed for 20 hr to
increasing dose of the virus (Figure 1D). The use of rapamycin
and/or chloroquine drugs, known to activate or inhibit auto-
phagolysosomal-dependent degradation events, respectively,
allows one to biochemically monitor autophagy flux. Accumula-
tion of LC3-II form in lysates of 12 hr rapamycin-pulsed iDCs
pretreated with chloroquine is representative of autophagy
induction (Figure 1E). LC3-II accumulation was not observed in
lysates of HIV-1-pulsed iDCs pretreated with chloroquine thus
arguing that HIV capture by iDCs does not increase autophagy
initiation (Figure 1E).
To ensure that HIV-1 alters autophagic flux, we analyzed
the amounts of p62 (also known as SQSTM1) in DCs. p62 inter-
acts with LC3 and links autophagy with degradation of polyubi-
quitinylated aggregates. Inhibition of autophagy is known to
lead to p62 accumulation and inefficient polyubiquitinylatedImmunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc. 655
Figure 1. Loss of LC3-II in HIV-1-Infected
DCs and MyDCs Is Due to a Block in the
Initiation Step of Autophagic Flux
(A) Confocal immunofluorescence analysis of LC3
(red) in unexposed iDC (NI) or 20 hr HIV-1-exposed
iDCs (HIV-1). DAPI (nucleus) is shown in gray.
Quantification of absolute number of LC3+ puncta
(lower graph). Data aremeans of 30 acquired fields
(±SD) and representative of three experiments.
Scale bars represent 5 mm.
(B) Confocal immunofluorescence of HIVGag
(green) and LC3 (red) in unexposed or HIV-1
pulsed MyDCs for 20 hr. Data are representative
of two independent experiments. Scale bars
represent 5 mm.
(C) The left panel shows immunoblot analysis
of LC3 in lysates of DC exposed to HIV-1 for
indicated times. The right panel shows quantifica-
tion of LC3-I and LC3-II levels normalized to
actin. Actin expression at time 0 was considered
100%. Data are means (±SD) of four independent
experiments.
(D) Graph representing quantification of LC3-II
normalized to actin in DCs (see representative
experiment in Figure S1). Error bars represent
the mean ± SD of three independent experiments.
(E) Lysates of iDCs, preincubated or not for 2 hr
with rapamycin (50 mg/ml) and/or 30min with chlo-
roquine (10 mM) when indicated and then left
untreated or treated with HIV-1 for 12 hr were
immunoblotted with anti-LC3 (upper panels).
Arrows indicate migration of LC3-I and LC3-II
forms. Equal sample loading was controlled with
anti-actin (lower panels). Data are representative
of three experiments.
(F) Immunoblot analysis of p62 in lysates of DCs
nonexposed (NI) or pulsedwith HIV-1 for indicated
times. Experiments were done in two donors.
(G) Immunoblot analysis of p62 in lysates of MyDC
nonexposed or pulsed with HIV-1 for indicated
times. Experiments were done in two donors.
(H) Confocal analysis of DC pulsed or not pulsed
with HIV-1 for 20 hr. Cells were fixed, permeabi-
lized, and stained with anti-HIV-1Gag (green),
anti-poly-Ub (red), and anti-Lamp1 (blue).
Quantification of poly-Ub fluorescence signal
intensity was measured in unexposed DCs (NI) or
DCs pulsed with increasing doses of HIV-1
(50–500 ng p24). Data are means of fluorescence
intensity (±SD) in 30 cells and representative of
two experiments. Scale bars represent 5 mm.
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2009). We observed a decrease in p62 in iDCs treated for 1 hr
with HIV-1, suggesting that initial autophagosome-mediated
p62 degradation was not affected early upon HIV-1 exposure
(Figure 1F). However, a strong increase in p62 expression
was observed in iDC exposed with HIV-1 for 10 hr, suggesting
a later block in p62 degradation (Figure 1F). Similar results
were obtained in MyDCs (Figure 1G). Furthermore, confocal
immunofluorescence analysis of HIV-1-pulsed iDCs showed
an increased content of polyubiquitinylated proteins compared656 Immunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc.to nontreated cells (NI) (Figure 1H). Quantification of polyubiqui-
tinylated proteins by confocal microscopy revealed a 2-fold
increase upon low-viral-dose treatment (20–50 ng p24) and
a 5.7-fold increase with higher viral doses (100–500 ng p24)
(Figure 1H).
These data suggest that HIV-1, though not affecting autopha-
gosome maturation during early events of iDC-mediated viral
capture, alters autophagy initiation leading to progressive
autophagy exhaustion and block in autophagosome-mediated
degradation.
Figure 2. HIV-1 Envelope Induces mTOR Signaling
Pathway Activation
(A) The upper panel shows an immunoblot of DC lysates
with PathScan I cocktail recognizing phosphorylated
mTOR pathway proteins after 15 min of HIV-1 exposure.
Arrows indicate bands corresponding to Erk and S6 phos-
phorylated proteins. Experiment shown is representative
of five independent experiments.
(B) Lysates of DC untreated or treated with HIV-1 or with
HIV-1-DEnv (500 ng p24 each) for 15min and immunoblot-
ted with PathScan I cocktail. Arrow indicates S6 phos-
phorylated protein. Data are representative of three inde-
pendent experiments.
(C) Immunoblot with PathScan I cocktail of lysates of DCs
untreated or treated for 15min with HIV-1 or HIV-1-F522Y.
Arrows indicate bands corresponding to Akt, Erk, and S6
phosphorylated proteins. Loading was controlled with
anti-actin (lower panel). Data are representative of two
experiments.
(D) PathScan I immunoblotting on lysates of 5 3 105 DCs
untreated or treated for 15 min with mouse Ig (10 mg/ml),
rabbit Ig (10 mg/ml), mouse anti-CD4 (10 mg/ml), rabbit
anti-DC-Sign (H-200 at 10 mg/ml), rgp120 (5 mg/ml), rantes
(10 nM), and HIV-1 (1 mg p24). Phosphorylated Erk and S6
migrating bands are indicated by arrows. Similar results
were obtained in three independent experiments.
(E) Lysates of DCs untreated or treated with HIV-1, HIV-1-
DEnv, or HIV-1-F522Y (500 ng p24 each) for 15 min
and immunoblotted with anti-phospho2448-mTOR. Arrow
indicates phosphorylated mTOR protein. Equivalent load-
ing was controlled by immunoblotting with anti-mTOR
(lower panel). Data are representative of three indepen-
dent experiments.
(F) Lysates of iDCs untreated or incubated for 12 hr with
HIV-1 (1 mg p24), Ig isotype (10 mg/ml), rgp120 (5 mg/ml),
and anti-CD4 (10 mg/ml) were immunoblotted with anti-
LC3 (upper panels). Loading was controlled with anti-actin
(lower panels). Data are representative of twoexperiments.
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Downregulates Autophagy in DCs
Mammalian target of rapamycin (mTOR) is a Ser-Thr kinase that
functions as a central regulator of biomass growth or loss by
affecting transcription, protein synthesis, mRNA stability, and
autophagy initiation (Pattingre et al., 2008). When activated,
rapamycin-sensitive mTOR complex 1 (mTORC1) upregulates
S6-kinase (S6K) involved in substrate phosphorylation of a range
of targets as ribosomal protein S6. Normally, mTOR inhibits
autophagy at initiation step, but under nutrient deprivation, rapa-
mycin treatment, or stress conditions, this inhibitory activity on
autophagy is relieved. The link between themTOR-S6K signaling
pathway and autophagy regulation led us to analyze whether
HIV-1 modulated this signaling pathway in DCs.
Lysates of iDCs exposed or not exposed with HIV-1 were
immunoblotted with a cocktail of polyclonal antibodies recog-
nizing phosphorylated forms of proteins involved in the mTOR
signaling pathway. iDCs exposed for 15 min with HIV-1 showedImmunity 32increased phosphorylation of ribosomal protein
S6 and Erk, the latter known to be upstream
of mTOR activation (Figure 2A, left panel).
Increased phosphorylation of S6 correlated
with LC3-II loss (data not shown), strongly sug-gesting that HIV-1-mediated mTOR signaling induced a block of
autophagy flux initiation leading to autophagosome exhaustion.
HIV-1 envelope-expressing HeLa cells have been shown to
induce syncitial apoptosis of CD4-expressing bystander HeLa
cells via a signal cascade involving mTOR (Castedo et al.,
2001; Castedo et al., 2002). Hence, interregulation between
mTOR and autophagy is often connected to apoptosis or cell
death (Edinger and Thompson, 2004). Therefore, autophagy
impairment could occur via a noncontrolled side effect of
mTOR activation on other signaling pathways involved in cell
growth or death. To rule out this possibility, we analyzed global
protein expression, cellular viability, and apoptosis in iDCs
treated for 20 hr with HIV-1 in presence or absence of mTOR
and autophagy modulators. At that time point in HIV-1-exposed
iDCs, we observed no substantial changes in global mRNA
content, cell size, cellular viability, or caspase-3 activity even in
presence of mTOR or autophagy modulators (rapamycin and
3-MA respectively) (Figure S2 and data not shown). Because, 654–669, May 28, 2010 ª2010 Elsevier Inc. 657
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as 15 min after HIV exposure, we hypothesized that HIV-1
induced the mTOR-S6K pathway activation via HIV-1 Env-medi-
ated signaling. By comparing HIV-1 wild-type (WT) and HIV-
1-DEnv, we observed that HIV-1-DEnv viruses were unable to
increase S6 phosphorylation (Figure 2B). Of note, both CXCR4
and CCR5-tropic HIV-1 could induce S6 phosphorylation
(data not shown). HIV-1-F522Y, a fusion-defective mutant virus
(Sourisseau et al., 2007), showed an increased phosphorylation
of S6 and Erk (Figure 2C). Thus, viral fusion is not required to
induce mTOR-S6K signaling in iDCs and subsequent inhibition
of autophagy in DCs (data not shown).
Next, we treated iDCs for 15 min with recombinant HIV-1
GP120 (rGP120), anti-CD4 and anti-DC-SIGN. HIV-1 GP120
and anti-CD4 could trigger S6 and Erk phosphorylation as effi-
ciently as wild-type virus (Figure 2D). In contrast, H-200, a DC-
SIGN agonist antibody, and Rantes and SDF-1a, ligands for
CCR5 and CXCR4, respectively, did not show any effect on S6
phosphorylation (Figure 2D and data not shown). Activation of
mTOR was confirmed to be envelope dependent, given that
HIV-1-WT, nonfusogenic HIV-1-F522Y, and rGP120 were able
to induce mTOR phosphorylation at serine residue 2448,
whereas this was not observed with HIV-DEnv (Figure 2E).
Engagement of iDC cellular receptors by HIV-1 and rGP120
was consistently correlated with a profound loss of autophago-
somal LC3 upon 12 hr of treatment (Figure 2F). However, CD4
engagement alone on iDCs by agonist antibodies, although
inducing signaling via the mTOR pathway, showed a slight
decrease of autophagosomal LC3 upon 12 hr of stimulation
(Figure 2F), suggestive of the possible need of synergic engage-
ment of other cellular receptors on iDCs to recapitulate the LC3-II
loss observed with HIV-1 envelope.
Together, these results indicate that HIV-1 Env triggers
signaling events, in part through the CD4 receptor, that lead to
mTOR activation, thereby downregulating autophagy initiation.
Therefore, viral fusion upon endocytosis is required for produc-
tive infection (Miyauchi et al., 2009) but not for HIV-1 Env-medi-
ated mTOR pathway activation.
HIV-1 Traffics to Lysosomes via Amphisomes
We hypothesized that HIV-1-mediated autophagy inhibition in
DCs could be a viral defense mechanism against autophago-
some-mediated viral degradation. This suggests that autopha-
gosomes could intersect HIV-1 upon DC-mediated viral capture.
Confocal immunofluorescence experiments showed colocaliza-
tion betweenHIV-Gag and LC3+ vesicles early after incubation of
HIV-1 with iDCs (Figure 3A). Upon 15 min of HIV-1 internalization
by iDCs, LC3+ structures were colocalizing with HIV-1 (Figures
3A and 3B). After 1 hr of virus contact, intracellular colocalization
between HIVGag and LC3+ profiles increased and were still
detected after 2 hr of iDC-mediated HIV-1 capture (Figures 3A
and 3B). At the 1 hr time point of HIV-1 incubation with iDCs,
we could identify autophagolysosomes costaining with anti-
Gag, anti-LC3, and anti-Lamp1 (Figure 3B), suggesting that
a proportion of HIV-1-containing autophagosomes fused with
lysosomes. Lysosomal inhibition by chloroquine allowed us to
readily detect LC3, Lamp1, and Gag at 15, 60, and 120 min after
viral internalization by iDCs (Figures 3A and 3B). Quantification of
viral trafficking to autophagosomes and lysosomes was per-658 Immunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc.formed in the presence or absence of chloroquine. In as early
as 15 min, we could observe a peak amount of virus present in
autophagosomes (Figure 3C). Chloroquine treatment increased
HIV-1 accumulation in LC3+ structures (Figure 3C). Of note,
whereas DC-SIGN agonist antibody H-200 did not show any
substantial effect on mTOR pathway activation (see Figure 2),
we observed DC-SIGN colocalizing with LC3+ structures after
10 min stimulation with HIV-1, gp120, and antagonist antibody
AZN-D1 (Figure S3). This suggests a potential link between
DC-SIGN binding and trafficking to autophagosomes, but rules
out a major role for DC-SIGN engagement in HIV-1-mediated
mTOR activation.
At later time points, the virus accumulated in lysosomes in the
presence of chloroquine (Figure 3D). Chloroquine treatment led
to the accumulation of LC3+Lamp1+ structures, suggestive of
increased autophagolysosomes in iDCs (Figure 3E). This effect
could be observed up to 20 hr (Figure 3H). We also analyzed
HIV-1 trafficking at later time points going from 2 hr to 20 hr
(Figure S3) and quantified colocalization events of HIV-1 Gag
with LC3+Lamp1+ structures. Colocalization of HIV-1 with LC3+
Lamp1+ structures peaked at 6 hr (Figures 3F and 3G) and
decreased after 12 hr, correlating with the loss of autophagoso-
mal LC3 at later time points. As observed for earlier time points,
chloroquine pretreatment of iDCs led to an increased HIV-1
colocalization, suggestive of a marked viral degradation medi-
ated by autophagolysosomal organelles (Figures 3F and 3G).
Together, these results indicate that upon endocytosis, HIV-1
is first routed via LC3+ autophagosomes, namely amphisomes,
and subsequently targeted to lysosomes for degradation.
To further define the LC3+ structures that colocalized with
HIV-1 at early time points after internalization, we estimated the
diameter of the HIV-1+LC3+ compartments. Z stacks of confocal
images revealed that HIV-1-containing amphisomes had a
diameter of 1.2 mm (Figure 3I) compatible with the average auto-
phagosomal size (Klionsky, 2005). Next, we performed electron
microscopy studies in iDCs unexposed or exposed for 2 hr with
HIV-1 to allow virus capture and internalization. In these condi-
tions, we could identify in DCs double-membrane autophago-
some-like structures (Figure S3, black arrows). A proportion of
thesestructurescontainedHIV-1 (FigureS3, right, blackasterisk).
Of note, thediameter ofHIV-1-containingamphisomesmeasured
on electron microscopy images was comparable to those in
untreated DCs ranging from 0.6 to 1.2 mm (data not shown).
Taken together, these results indicate that intracellular LC3+
structures in DCs can intercept engulfed virions and target
them toward lysosomal degradation. These events are reminis-
cent of structures called amphisomes formed upon fusion
between endosomes and autophagosomes.
Autophagy Downregulation Leads to Increased HIV-1
Content in DCs
LC3, apart frombeing an autophagosomal marker, is also a regu-
lator of autophagosome formation during membrane expansion
and the final closing step of the vesicle (Geng and Klionsky,
2008; Nakatogawa et al., 2007). To explore the impact of
autophagosomal machinery on HIV-1 capture by DCs, we
transfected DCs with control siRNA (Ctrl) or siRNA directed
against LC3 isoforms a and b. An efficient downregulation of
LC3 expression of 60%–95% with siRNA directed against LC3
Figure 3. HIV-1 Traffics via Autophagosomes Prior to Lysosomal Targeting
(A) Confocal immunofluorescence analysis of HIV-1Gag (green), LC3 (red), and Lamp1 (blue) of DCs pretreated or not with chloroquine (10 mM) and exposed to
HIV-1 for indicated times. White arrows indicated colocalization between HIV-1Gag (green) and LC3 (red). Data are representative of three independent exper-
iments.
(B) Magnification of areas of HIV-1Gag colocalizing with LC3+ positive structures indicated by white arrows in (A).
(C) Quantification of autophagosomes (LC3+) colocalizing with HIV-1Gag at each indicated time in presence or absence of chloroquine (Chlq). Data are means of
at least 20 cells per condition (±SD) at each time and representative of three independent experiments.
(D) Quantification of lysosomes (Lamp1+) colocalizing with HIV-1Gag at each indicated time in presence or absence of chloroquine (Chlq). Data are means of at
least 20 cells (±SD) per condition at each time and representative of three independent experiments.
(E) Quantification of lysosomes (Lamp1+) colocalizing with autophagosomes (LC3+) at each indicated time in presence or absence of chloroquine (Chlq). Data are
means of at least 20 cells (±SD) per condition at each time and representative of three independent experiments.
(F–H) The same as in (C)–(E) respectively but during longer time points. Data are means of at least 15 cells and representative of two experiments.
(I) DC exposed to HIV-1 for 120 min and processed as in (A). Z stack confocal analysis was done with slices of 1 mm. The image is from one field out of 20 and
representative of three independent experiments.
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Figure 4. Autophagy Inhibition in DCs Leads to Increased Cell-Associated HIV-1 Gag
(A) Lysates of DCs nontransfected (NT), transfected with siCtrl, or transfected with siLC3 were immunoblotted with anti-LC3. LC3-I and LC3-II are indicated by
arrows. Typical downregulation of LC3 expression in DCs with siLC3 ranged from 60% to 95%.
(B) siCtrl DCs or siLC3 DCs unexposed or exposed for 20 hr with HIV-1 were processed for confocal immunofluorescence analysis and stained with anti-HIV-
1Gag (green) and anti-LC3 (red). Scale bars represent 5 mm.
(C) FACS analysis of HIV-1Gag intracellular staining in unexposed or DC exposed for 20 hr with HIV-1. DCs preincubated with AZT served as control to prevent
viral replication.
(D) Mean fold of increase of HIV-1Gag+ cells determined by FACS data from five different experiments. Nontransfected DC exposed with HIV-1 were set to an
arbitrary value of 1. Error bars represent the mean ± SD of the five independent experiments.
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(NT) and siRNA Ctrl-treated DCs (Figure 4A). Downregulation of
LC3 expression in siLC3-treated DCswas confirmed by confocal
immunofluorescence and compared to siCtrl-DC (Figure 4B).
HIV-1 exposure during 20 hr on siCtrl-DCs recapitulated LC3-II
loss as previously described (Figure 4B). Strikingly, siLC3-
treated DCs showed increased HIVGag+ cells with a more scat-
tered HIVGag staining per cell (Figure 4B). Increased HIV-1
content in autophagy-deficient iDCs was also confirmed by
intracellular HIVGag staining and FACS analysis (Figure 4C).
Intracellular HIVGag staining in siLC3-treated DCs showed on
average a 2.2 fold (±0.74) increase in HIV-1 content compared
to NT and siCtrl DCs (Figure 4D). This effect was virus replication660 Immunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc.independent as demonstrated with a reverse transcriptase inhib-
itor (AZT) treatment (Figure 4D). To rule out nonspecific effects
with siLC3, we repeated similar experiments but targeting
another autophagosomal protein, ATG5, a main regulatory
component of autophagosome formation (Mizushima et al.,
1998). siATG5-DCs had a similar increase of HIV-1 content
when compared to control cells (Figure S4). In order to define
whether HIV-1 activation of mTOR occurs upstream of inhibition
of autophagy by the virus, we analyzed mTOR activation by
HIV-1 in autophagy-deficient or drug-treated DCs. Strikingly, we
observed a defect in activation of phospho-mTOR (on S2448)
and mTOR signaling upon HIV-1 treatment in siATG5 and
siLC3 DCs compared to siCtrl DCs (Figure S4). In fact, mTOR
Figure 5. Autophagy Inhibition in DCs Leads to Increased Viral Cell-to-Cell Transfer
(A) HIV-1 transfer (stainedwith anti-HIVGag) from nontransfected (NT), siCtrl, and siLC3 DCs to autologous CD4+ T cells (stained with anti-CD3) previously treated
with indinavir (2 mg/ml).
(B) Mean values (±SD) of NT, siCtrl, and siLC3 DC-mediated HIV-1 transfer to CD3+/CD4+ autologous T cells from four independent experiments with increasing
amounts of viral input (2–200ng p24).
(C) Trans-infection mediated by iDCs or mDCs pulsed with HIV-Luc/JRFL and treated or untreated with rapamycin (50 mg/ml) and then cocultured with CD4+
T cells (Hut-CCR5). Luciferase activities were quantified in cell lysates. Cps, counts per second. All data show the mean ± SD of duplicate or triplicate samples.
One representative experiment out of three is shown.
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cells were stimulated with PMA, a well-known activator of mTOR
signaling (Figure S4). Therefore, our results indicate that HIV-1-
mediated mTOR activation occurs upstream of inhibition of
autophagy (see Figure 2).
Autophagy Downregulation Enhances in trans
DC-Mediated HIV Transfer to CD4+ T Cells
We next wondered whether DC-mediated HIV-1 transfer in trans
to CD4+ T cells could also be affected in autophagy-deficient
DCs. NT, siCtrl, and siLC3 DCs were exposed with HIV-1 for
8 hr before coincubationwith autologousCD4+ T cells pretreated
with the viral protease inhibitor indinavir, precluding any produc-
tive infection in target cells. With siLC3-DCs, HIV-1 transfer to
CD4+ T cells was increased compared to siCtrl DCs (3.3 and
2.5 times greater with low and high viral dose, respectively)
and to NTDCs (Figures 5A and 5B). Of note, siATG5DCs showedan even more pronounced stimulation of transfer of HIV-1 infec-
tion to autologous CD4+ T cells, confirming that this effect was
due to inhibition of the autophagosomal machinery (Figure S5).
Rapamycin is a macrolide, known to induce autophagy via
mTOR inhibition, and is considered a promising drug in multiple
application ranging from cancer, aging, and neurodegenerative
diseases (Rubinsztein et al., 2007). To investigate whether
autophagy can block DC-mediated HIV-1 trans-infection, we
compared viral transmission to CD4+ T cells between control
and rapamycin-treated DCs. HIV-1 pseudotyped with the R5-
tropic HIV-1 Env was used (Wang et al., 2007). As a background
control, no detectable infection was found in HIV-pulsed DCs
without T cell cocultures. Mature DCs (mDCs) were already
shown to more efficiently transfer infection toward target cells
and thus served as positive control. When DCs were cocultured
with CD4+ T cells, mDC-enhancedHIV-1 trans-infection of T cells
was 7-fold more efficient (p < 0.0001) compared with iDCs asImmunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc. 661
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1-pulsed DCs significantly reduced iDC- and mDC-mediated
HIV-1 transmission by 52% and 56% (p < 0.001), respectively.
In addition, rapamycin treatment with DCs did not result in
cytotoxic effects (see Figure S2). These data suggest that
rapamycin-induced autophagy in DCs impairs DC-mediated
HIV-1 trans-infection.
HIV-1 Induced Autophagy Downregulation Alters DC
Responses to TLR Ligands
Autophagy has been involved in positive regulation of some TLR-
mediated innate immune response upon pathogen invasion
(Delgado et al., 2009; Levine and Deretic, 2007). In addition,
TLR responses alterations in DCs and macrophages from HIV-
positive patients have been reported (Martinson et al., 2007;
Nicol et al., 2008). We thus wondered whether HIV-1-induced
autophagy downregulation could explain altered DC responses
to specific TLR ligands. We first screened which TLR ligands
could mediate a TNF-a response in DCs. Efficient TNF-a
responses upon TLR3, TLR4, TLR6, and TLR8 stimulation were
observed in iDCs, as expected (Figure S6). DCswere transfected
with siCtrl, siLC3, and siATG5 and protein expression was
controlled by immunoblotting (Figure 6A). When stimulated
with LPS via TLR4, siLC3-treated-DC and siATG5-DC intracel-
lular TNF-a responses were significantly reduced by more than
60% and 80%, respectively, compared to those of siCtrl DCs
or untreated DCs (Figures 6B and 6C), and TLR8-mediated
responses were also significantly reduced by more than 50%
in both conditions (Figure 6D). HIV-1 exposure also reduced
significantly TLR4- and TLR8-mediated intracellular TNF-a pro-
duction to 50% and 64% respectively (Figures 6C and 6D), in
agreement with the loss of LC3-II observed in these condi-
tions (Figures 1 and 2). HIV-1 capture, however, only slightly
decreased siLC3-DC and siATG5-DC TLR signaling (Figures
6C and 6D), in accordance with the expectation that most of
HIV-1 impact on TLR4- and TLR8-mediated responses is
autophagy dependent. Importantly, recombinant HIV-1 enve-
lope could also decrease cytokine response upon LPS stimula-
tion (Figure 6E). Of note, CD4 engagement alone was not able
to fully recapitulate the inhibition mediated by HIV-1 envelope
of LPS-dependent responses (data not shown). An efficient
TLR-mediated response mostly relies on a well-coordinated
receptor-ligand localization and/or well-regulated signaling
cascades leading to critical transcription factors activation. In
order to elucidate how HIV-1 and autophagy impairment could
interfere with TLR-mediated responses, we investigatedwhether
TLR4-mediated NF-kB signaling pathway was altered in HIV-
1-treated and autophagy-deficient DCs. When compared with
untreated DCs (NI), HIV-1-treated DCs showed a reduced
phospho-IKK-a and -b pattern upon 15 min of LPS stimulation
(Figure 6F). This correlated with less NF-kB phosphoryla-
tion because of decreased phosphorylation-dependent IkB-
a degradation via the proteasome (Figure 6F). Interestingly,
DCs exposed for 20 hr with HIV-1-DEnv were not altered in
TLR4-mediated NF-kB pathway activation (Figure 6F), Defective
NF-kB pathway activation was even more pronounced in
autophagy-deficient cells when comparing siLC3 and siATG5
DCs to siCtrl DCs upon LPS stimulation (Figure 6G). Similar
results were obtained with siBeclin1 DCs (data not shown).662 Immunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc.These results suggest that autophagy could regulate TLR-medi-
ated signaling upstream of IKK complex activation.
Autophagy Is Required for HIV-1-Antigen Processing
and Presentation to HIV-Specific CD4+ T Cells
Autophagy has recently been reported to be a key regulator of
adaptive immune responses (reviewed in Deretic, 2009; Mu¨nz,
2006) by controlling intracellular antigen targeting to MHC-II
compartments (Dengjel et al., 2005; Paludan et al., 2005; Schmid
et al., 2007). Despite growing evidence of an intersection
between autophagy and endocytosis (Liang et al., 2008; Razi
et al., 2009), few reports demonstrate a clear role for autoph-
agy-mediated extracellular antigen presentation after pathogen
entry. We took advantage of our previously described model of
HIV-1-derived antigen presentation to HIVGag-specific (HS)
CD4+ T cell clones (Moris et al., 2006) to study the role of autoph-
agy on exogenous HIV-1 antigen presentation on MHC II. Intra-
cellular FACS revealed a striking reduction in HS CD4+ T cell
clone TNF-a responses when we used HIV-1-pulsed siLC3 DC
compared to HIV-1 pulsed NT DCs or siCtrl DCs (Figure 7A).
The decrease of siLC3-DC-mediated HS CD4+ T cell responses
was of 3-fold and 4.5-fold (Figure 7B, upper panel).
As positive controls, NT DCs, siCtrl DCs, and siLC3 DCs incu-
bated with cognate Gag peptide (Moris et al., 2006) showed effi-
cient and similar HS clone responses (Figure 7A and the lower
panel of Figure 7B), thus ruling out a defective MHC class II
expression at the cell surface in autophagy-deficient cells, as
controlled by HLA-DR cell surface staining (Figure S7). Quantita-
tive HIVGag-specific (HS) IFN-g responses by ELISPOT assays
of CD4+ T cell clones confirmed defective DC-mediated exoge-
nousMHC II antigen presentation when autophagy was inhibited
(Figure 7C, left panel). In ELISPOT assays, NT DCs, siCtrl DCs
and siLC3 DCs incubated with cognate Gag peptide (Moris
et al., 2006) showed efficient and similar HS clone responses
as expected. Inefficient exogenous MHC-II antigen presentation
was apparently not due to a global maturation defect in siLC3
DCs given that these cells were capable of maturation (upregu-
lation of cell-surface CD83 and HLA-DR molecules compared
to NT DCs and siCtrl DCs) upon IL-1b, TNF-a, and CD40L
stimulation (Figure S7). Exogenous MHC-II-mediated antigen
presentation toward the HS clone was also affected when
siATG5-DC were used (Figure S7). Of note, while our study
was under revision and in agreement with our results, a recent
article showed that Atg5/ DCs in a murine system had altered
HSV-1-derived exogenous antigen processing and presentation
thus leading to impaired CD4+ T cell priming (Lee et al., 2010). In
addition, we did not find a deficit in DCmaturation of autophagy-
deficient DCs (see Figure S7), and we also ruled out a major role
of autophagy in MHC-I cross-presentation. Indeed, MHC-I
cross-presentation to HS CD8+ T cell clones was not altered
when autophagy was inhibited by 3-MA in DCs loaded with
HIV-1 (Figure S7).
We next analyzed by ELISPOT assays whether pharmacolog-
ical modulation of autophagy induction could affect DC-medi-
atedHIV-1processingandantigenpresentation to theHSclones.
DC pretreatment with 3-methyladenine (3-MA), a well-known
autophagy inhibitor, reproduced the decreased antigen-medi-
ated HS clone response observed with siLC3 DCs (Figure 7E)
in which LC3 expression was monitored by immunoblotting
Figure 6. RNA Interference or HIV-1-Mediated Autophagy Inhibition Dampen TLR4- and TLR8-Mediated Responses in DCs
(A) Immunoblot analysis of LC3 and ATG5 expression in lysates from siCtrl, siLC3, and siATG5 DCs. Arrows denote LC3-I and LC3-II migrating forms.
(B) FACS analysis of TLR4-mediated intracellular TNF-a response upon 20 hr LPS stimulation of siCtrl, siLC3, or siATG5 DCs previously unexposed (NI) or pulsed
with HIV-1 for 8 hr. BrefeldinA (10 mg/ml) was added 1 hr after adding LPS.
(C) TNF-a responses upon 20 hr TLR4 stimulation in non-transfected (NT), siCtrl, siLC3, and siATG5 DCs. Response was normalized to nonstimulated NT-DCs,
and depicted as fold increase over control. Data represented means (±SD) of fold increase in TNF-a responses from five independent experiments.
(D) TNF-a responses in DCs exposed or not with HIV-1 for 8 hr and then stimulated with TLR8 agonist for 20 hr. Response was normalized to nonstimulated NT
DCs and depicted as fold increase over control. Data represented means (±SD) of fold increase in TNF-a responses from five independent experiments.
(E) FACS analysis of TLR4-mediated intracellular TNF-a response upon 20 hr LPS stimulation of nontransfected (NT), siCtrl, or siLC3 DCs previously unexposed
(NI) or pulsed with HIV-1 or rgp120 (5 mg/ml) for 8 hr. BrefeldinA (10 mg/ml) was added 1 hr after adding LPS. Intracellular TNF-a response was normalized to
unstimulated NT DCs and represented on a graph (right) as fold increase over control. One representative experiment out of three is shown.
(F) DCs untreated (NI), or treated with HIV-1 or HIV-1-DEnv for 20 hr, were kept unstimulated or stimulated with LPS (1 mg/ml) for 15 min, in presence or
absence of proteasome inhibitor Mg132 pretreatment when indicated (30 min at 1 mM). Lysates were then immunoblotted with anti-p176/180-IKKa/b, anti-
IKK-a, anti-p32 IkB-a, anti-IkB-a, anti-p536 NF-kB, and anti-NF-kB. Sample loading was controlled with anti-actin. One representative experiment out of three
is shown.
(G) The same experiment as in 6F was done on siCtrl, siATG5, and siLC3 DCs. One representative experiment out of three is shown.
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Figure 7. Autophagy-Deficient DCs Are
Altered in HIV-1-Derived Antigen Process-
ing and MHC Class II-Mediated Presenta-
tion to HIV-Specific T Cells
(A) FACS analysis of intracellular TNF-a response
in HIV-specific CD4+ T cells (CD3+) upon 8 hr
coculture with nontransfected (NT), siCtrl, and
siLC3 DCs previously pulsed for 20 hr with 100 ng
p24 HIV-Mn/AT2. A positive control was done in
parallel with DC pulsed for 20 hr with cognate
Gag peptide (0.5 mg/ml). BrefeldinA (10 mg/ml)
was added 1 hr upon coculture.
(B) Mean values of n-fold of increase of intracel-
lular TNF-a responses from three independent
experiments after pulsing DC with HIV-1 (upper)
or Gag peptides (lower). Basal HIV-specific CD4+
T cells’ intracellular TNF-a expression was used
as an arbitrary value of 1.
(C) ELISPOT assays measuring HIV-specific CD4+
T cells’ IFN-g responses upon coincubation for 36
hr with nontransfected (NT), siCtrl, and siLC3 DCs
previously pulsed for 20 hr with 100 ng p24 HIV-
Mn/AT2 (left) or Gag peptide (right). Mean values
(±SD) from one representative experiment is
shown. Results are representative of three exper-
iments performed in triplicates.
(D) Immunoblot analysis of LC3 expression in siCtrl
and siLC3 DCs. Arrows indicate LC3-I and LC3-II.
(E) HIV-specific CD4+ T cells IFN-g responses
measured by ELISPOT upon 36 hr coincubation
with HIV-1 pulsed DCs previously transfected
with siCtrl or siLC3 or pretreated for 2 hr with
rapamycin (10 mM), 3-MA (1 mM), or chloroquine
(20 mM). The right panel shows HIV-specific
CD4+ T cells’ IFN-g responses upon stimulation
with Gag-peptide pulsed DCs. Experiments were
done in triplicates (±SD).
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impaired HIV-1 antigen processing and presentation (Figure 7E).
Strikingly, when DCs were pretreated with rapamycin, we
observed a strong stimulation of HS clone IFN-g responses, up
to ranges that could only be obtainedwith a cognateGagpeptide
(Figure 7E). In contrast, rapamycin had no effect on HS clone
IFN-g responses to DCs loaded with cognate Gag peptide, as
expected (Figure 7E). This demonstrates that HIV-1, by downre-
gulating autophagy, can reduce DC-mediated antigen process-
ing and exogenous MHC II presentation. However, the inhibition
by the virus could be bypassed by rapamycin-mediated stimula-
tion of autophagy.
DISCUSSION
Although a large fraction of HIV-1 is degraded byDCs, a substan-
tial amount of virus can escape this degradation and is efficiently664 Immunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc.transferred to CD4+ T cells. We provide
evidence that HIV-1 shuts down autoph-
agy in DCs. The two key consequences
of the inhibition of autophagy in DCs,
which likely contribute to the subsequent
immunological events and inability to
control the virus, are the downregulationof TLR responsiveness in DCs and inhibition of HIV-derived
antigen presentation by DCs to CD4+ T cells. The effects of
HIV-1 on autophagy are dependent on Env interaction with DC
surface receptors, most likely CD4, and involve induction of
mTOR signaling. In agreement with the latter, rapamycin could
overcome HIV effects on autophagy. Furthermore, rapamycin
diminished HIV-1 transfer from DCs to target T cells. Thus,
autophagy plays a multitude of roles in the early events during
HIV-1 infection with immediate consequences on infection of
T cells and TLR signaling by DCs, as well as in antigen presenta-
tion events that set up adaptive immune responses to HIV.
DCs have a specialized endo-phagocytic machinery that links
protein-pathogen capture and degradation to broad and potent
innate and adaptive immune response (Iwasaki, 2007; Mellman
and Steinman, 2001). Autophagy is an essential cellular process
that leads to pathogen digestion and importantly an enhance-
ment mechanism implicated at several steps in the activation
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2007; Mu¨nz, 2007; Orvedahl and Levine, 2008). Despite some
reports of RNA viruses able to co-opt autophagy for their own
replication (Jackson et al., 2005), autophagy has been mainly
described as a defense mechanism against other DNA virus
infections such as HSV-1, CMV, or EBV.
As demonstrated in our study, HIV-1 capture in DCs leads to
a rapid loss of autophagosomes. Upon HIV-1 exposure of mono-
cyte-derived DCs or MyDCs, we observed a strong decrease of
autophagosomal LC3 (LC3-II) by confocal immunofluorescence
and by immunoblotting experiments. HIV-1-mediated loss of
LC3-II could be observed as early as 1 hr of HIV-1 internalization
by DCs and reached a maximum effect after 10–20 hr. Intrigu-
ingly, after 20 hr of HIV-1 exposure, we also observed a disap-
pearance of total LC3 and other ATG proteins (ATG5, ATG7,
and Beclin-1) (data not shown); such a result could be explained
by additional mechanisms such as an HIV-1-mediated effect on
transcription or translation or effects related possibly to de novo
virus replication. Our findings are in agreement with an inhibition
of autophagy observed in HIV-1-infected CD4+ T cells, including
a decrease of LC-3 at the protein and mRNA level (Zhou and
Spector, 2008).
A recent report from Harman et al. (2009) showed that HIV-1
de novo replication in DCs after 48 hr markedly diminished
cathepsin activity as a result of decreased expression of cathep-
sins B, C, S, and Z. The authors proposed that decreased
lysosomal cathepsin activity could probably result in enhanced
HIV-1 survival and transfer to contacting T lymphocytes but
decreased HIV-1 antigen processing and presentation to these
T cells. Thus it seems that HIV-1, by impairing autophagy induc-
tion upon early events of viral capture as well as lysosome prote-
ases expression at later times during de novo replication, has
developed means to counteract lysosome-mediated degrada-
tion during the two temporal phases of HIV-1 interaction with
DCs.
The early impact of HIV-1 on LC3-II loss in DCs was clearly
linked to a block in the autophagic flux, as demonstrated by
p62 and polyubiquitinylated aggregates accumulation in DCs.
We could also demonstrate the presence of HIV-1 in LC3+ am-
phisomes as early as 15 min after virus endocytosis. The block
in autophagy in DCs induced by HIV-1 could be explained by
the fact that HIV-1 envelope induced activation of the mTOR
signaling pathway, the main regulator of autophagosome
formation. By downregulating expression of critical autophagy
regulators (LC3 and ATG5), we observed that HIV-1 content
was increased in autophagy-deficient DCs, correlating with
enhanced DC-mediated HIV-1 transfer in-trans to autologous
CD4+ T cells. Rapamycin pretreatment could strongly decrease
both HIV-1 content (data not shown) and DC-mediated viral
transmission, thus revealing a possible tool to enhance autoph-
agy-mediated HIV-1 restriction.
Autophagy, in addition to providing some defense against
specific pathogens, is emerging as a potential regulator of
TLR-mediated innate immune responses (Delgado et al., 2009;
Sanjuan et al., 2007). Therefore, we analyzed whether HIV-1-
mediated inhibition of autophagy could impact TLR-dependent
innate immune responses. We clearly demonstrated that both
autophagy-deficient cells (with RNAi targeting LC-3 and ATG5)
and DC-mediated HIV-1 capture led to alteration of both TLR4-and TLR8-mediated responses at least partly because of a nega-
tive impact on NF-kB signaling. Our data in si-ATG5 or siLC-3
DCs suggest that immunoamphisomes could increase TLR
signaling possibly by regulating TLR-ligand delivery. Similar
observations were reported previously in Atg5/ murine pDCs
(Lee et al., 2007). In contrast, mice deficient in Atg16L did not
show defects in TLR signaling (Saitoh et al., 2008). It is therefore
possible that TLR signalingmodulation by autophagymay be cell
type specific or alternatively that only certain components of
the autophagosomal machinery are critical for TLR signaling.
Of note, we also observed autophagosome accumulation in
LPS-stimulated DCs (data not shown), confirming that TLR4
engagement could upregulate autophagy in agreement with
results reported previously in macrophages (Xu et al., 2007).
Decreased TLR-4 response was also observed after treatment
of DCs with recombinant HIV-1 envelope. The fact that HIV-1
could modulate autophagy-mediated innate immune responses
in DC provides a potential explanation for several observations
indicating that DC infected with HIV-1 are less able to mount
proper immune responses (Granelli-Piperno et al., 2004; Kawa-
mura et al., 2003).
Autophagy has mainly been involved in MHC-II-mediated
antigen presentation from intracellular sources despite some
evidences of involvement of autophagosomes upon pathogen
endocytosis (Amer et al., 2005; Razi et al., 2009). Here, we
provide evidence that autophagy is also crucial for exogenous
antigen presentation on MHC II in the context of HIV-1 infection.
Although global maturation processes seemed unaffected,
LC3-deficient DCs were strongly altered in antigen processing
upon HIV-1 exposure, thus leading to greatly decreased
HIV-specific T cell responses. This defect in autophagy-medi-
ated exogenous HIV-1 antigen presentation on MHC II was
confirmed in DCs gene-targeted for ATG5 and beclin-1. Finally
we demonstrate in this study, using the drug rapamycin, that
stimulating autophagy in DCs prior to HIV-1 exposure could
powerfully boost DC-mediated adaptive immune responses.
Importantly, HIV-specific T cell responses obtainedwith rapamy-
cin-treated DCs appear to be optimal when observed with
DC-mediated presentation of cognate peptide. Enhancing
immune responses by autophagy activation is now gaining
more attention (Mu¨nz, 2009). Jagannath et al. (2009) demon-
strated that autophagy activation in DCs by rapamycin led to
enhanced in vitro and in vivo mycobacterial antigen Ag85B
presentation, and additional data are now available on the role
of autophagy in antigen presentation to CD8+ cells (Uhl et al.,
2009). Related to the above, English et al. (2009) revealed a class
of autophagosomes induced upon hyperthermia or IL-1b stimu-
lation able to enhance viral peptides processing and loading on
MHC I molecules upon HSV-1 infection. A recent report from
Sanjuan et al., (2007) described autophagy requirement for
TLR-dependent phagosomal maturation in macrophages. The
authors observed the TLR-dependent recruitment of autophago-
somal component to phagosome probably required for efficient
phagosomal maturation and enhanced killing of ingested
organism (Sanjuan et al., 2007). In contrast to the impact of
HIV-1 inhibition of autophagy inDCsonMHC II presentation, inhi-
bition of autophagy in DCs with 3-MA did not substantially alter
HIV-1 cross-presentation on MHC I. This indicates that autoph-
agy increases processing and presentation of HIV antigens onImmunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc. 665
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after virus capture by DCs.
In our study, we describe LC3+ autophagosomal-like struc-
tures that are able to intersect with HIV-1 endocytosis and that
probably regulate DC-mediated innate and adaptive immune
responses. We propose thus to term such structures ‘‘immu-
noamphisomes’’ because of their link between autophagy and
endocytosis and their function to amplify innate and adaptive
immune responses.
Our data indicate that mTORmodulation could be a promising
target to restrict early events of HIV-1 infection, while at the same
time increasingMHC II immune responses against the virus. One
potential problem of these approaches is that rapamycin and
analogs have immunosuppressive capacities in addition to their
potential immunostimulatory properties. In addition, rapamycin
is not extremely efficient at simulating autophagy in human cells
(Thoreen and Sabatini, 2009). New generations of inhibitors of
mTOR might address these problems (reviewed in Guertin and
Sabatini, 2009).
Animal models of mucosal transmission upon SIV challenges
in vivo have now clearly established that immune responses
against SIV (and by extension HIV) in mucosal tissues occur
‘‘too little, too late’’ and are insufficient to control subsequent
propagation of the virus (Li et al., 2009b). Part of the problem
appears to be unwarranted inflammation in tissues that
increases number of potential immune targets at sites of virus
infection. In support of this concept is the fact that glycerol
monolaurate, which is anti-inflammatory, appears to havemicro-
bicidal properties against SIV infection (Li et al., 2009a). Derived
from our studies of HIV-1 infection of DCs, we propose that
mTOR inhibitors such as rapamycin and potentially newer
more potent inhibitors would provide at least three benefits to
the host during the early stages of HIV-1 infection. First, mTOR
inhibitors, by activating autophagy, would lead to more efficient
virus degradation by DCs and thereby offer less capacity of viral
transmission to targets cells including CD4+ T cells and macro-
phages. Second, we showed that intact autophagy is required
to mount proper TLR response in HIV-1 infected DCs. Third,
stimulation of autophagy in DCs leads to more rapid and robust
adaptive immune responses. Therefore stimulation of autophagy
in the early events of HIV-1 infection could represent a novel
method to ‘‘robustly and rapidly’’ mount efficient immune
responses in mucosal tissues, thereby containing viral propaga-
tion. Our study, by demonstrating a critical role for autophagy
in the early events of HIV-1 infection, yields important insights
into the development of ‘‘rational’’ anti-HIV vaccines and current
approaches aiming to prevent HIV-1 transmission.EXPERIMENTAL PROCEDURES
Cells
Human monocytes from buffy coats were obtained in accordance with
institutional guidelines of the ethical committee of the University of Geneva.
Monocytes were purified after Ficoll gradient separation with CD14 MicroBe-
ads (Miltenyi Biotec). Usual purity was >95% CD14+. Human MDDCs were
generated by incubation of purified monocytes in IMDM supplemented with
10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin,
10 mM HEPES, 1% nonessential amino acids, 1 mM sodium pyruvate,
500 IU/ml GM-CSF, and 500 IU/ml IL-4 (both from Strathman Biotec,
Germany). On days 2 and 4, a third of the culture medium was replaced by666 Immunity 32, 654–669, May 28, 2010 ª2010 Elsevier Inc.fresh medium containing GM-CSF and IL-4. iDCs were harvested at day 6
and analyzed by flow cytometry. Autologous CD4+ T lymphocytes andmyeloid
DCs (MyDCs) were purified with CD4+ T Cell Isolation kit II and CD1c Dendritic
Cell Isolation Kit (Miltenyi Biotec), respectively, in accordance with the manu-
facturer’s instructions. Hut-CCR5 cell line (Wang et al., 2007) and autologous
CD4+ T lymphocytes were maintained in supplemented RPMI1640. 293T
human embryonic kidney cells and HeLa P4-R5 (NIH AIDS Research & Refer-
ence Reagent Program) cells were maintained in supplemented DMEM.
Virus Production
Virus stocks were produced as previously described (Arrighi et al., 2004).
In brief, 293T cells were transiently transfectedwith calcium-phosphate copre-
cipitated proviral plasmid pR9 or pR8-Bal, encoding for full-length HIV-1 X4
and HIV-1 R5 strain provirus, respectively. Infectious titers of viral stocks
were evaluated by limiting dilution on HeLa P4-R5 cells. These cells derive
from HeLa P-4.2 cells stably expressing coreceptor CCR5 and containing
the b-gal gene under the control of HIV long terminal repeat (LTR). Viral titers
were expressed as infectious units (IU) per ml. Approximately 500 ng of
p24gag on 2.53 105 CD4+ HeLa P4-R5 corresponds to aMOI of 1 (multiplicities
of infection). Physical titers were evaluated by quantification of anHIV-1 p24gag
by ELISA kit (Beckman Coulter, Paris, France).
Drugs
All chemicals were obtained from Sigma unless stated otherwise. For transfer
and capture assays, 2 mg/ml indinavir (Merck) and 50 mg/ml zidovudine (AZT)
(GlaxoSmithKline) were used. High-grade rapamycin was a kind gift from
J. Curran.
Antibodies and Reagents
Antibodies against LC3 (F14), ATG5 (N18), p62 (SQSTM1) (H-290), and
DC-SIGN (H-200) were from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-active Caspase-3, anti-CD4, anti-hTNF-a-APC, and FACS antibodies
were obtained from BD Transduction Laboratories (Franklin Lakes, NJ).
Anti-LC3 (PM036) used for immunoblotting was from MBL International
(Woburn, MA). Anti-poly-Ub (FK2) was from BIOMOL (Exeter, UK). Anti-
Lamp1 was from Abcam (Cambridge, UK). Anti-phospho2448-mTOR, anti-
mTOR, NF-kB pathway kit, and PathScan Multiplex cocktails I and III were
from Cell Signaling Technology (Danvers, MA). Anti-actin was from Sigma
(St-Louis, MO). Monoclonal anti-HIVgag (KC57-FITC, from Beckman Coulter,
Miami, FL) was used for immunofluorescence-confocal analysis as well as for
flow cytometry analysis. DAPI (40,60 di amidino-2-phe´nyl indole) was obtained
from Molecular Probes. Recombinant HIV-1 gp120 (rgp120 HIV-1 IIIB) was
from Immunodiagnostics (Woburn, MA). Soluble recombinant human CD40L
and Enhancer were from Apotech (Epalinges, Switzerland). Recombinant
human IL-1b and TNF-a were from Peprotech (London, UK).
siRNA Transfections
siCtrl ([50-AAATGAACGTGAATTGCTCAA-30]; siRNA sequence specific for
Luciferase), siBecn1 ([50-AAGATCCTGGACCGTGTCACC-3]; siRNA sequence
specific for Beclin-1) were synthesized from QIAGEN (Hilden, Germany).
Alternatively, the following siRNA mixes were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA): siLC3-a (sc-106197), siLC3-b (sc-43390),
and siATG5 (sc-41445). HiPerFect Transfection Reagent (QIAGEN, Hilden,
Germany) was used for transfection in accordance with the manufacturer’s
recommendations. In brief, 4 3 105 iDCs were usually transfected with
100 nM siRNA in 500 ml of IMDM/1% SVF medium in 12-well plates. A second
round of transfection was performed 24 hr later. Specific gene knockdowns
were assessed by immunoblotting followed by densitometry analysis (Quantity
One; Bio-Rad Laboratories, Hercules, CA) comparing with nontransfected and
siCtrl conditions.
Infections
For biochemical experiments, 106 of iDCs or 5 3 105 of MyDCs were plated
in 96-round well plates in 100 ml IMDM for challenge with R9-HIV-1 or
R8Bal-HIV-1 at MOI ranging between 0.2 and 2 (corresponding to 1 mg of
p24gag per 4 3 105 DCs). Cells were left in contact with virus during indicated
times at 37C. Cells were then resuspended in IMDMand processed for exper-
iments. For cellular assays, when not stated, HIV-1 treatment was done at
Immunity
Autophagy Exhaustion by HIV-1 Alters DC Functions500 ng p24 HIV for 2.5 3 105 cells (corresponding to a MOI of 1) and adapted
depending on cell number.
Immunoblotting
Cells were lysed for 20 min at 4C in lysis buffer (20 mM Tris [pH 7.5], 150 mM
NaCL, 1% NP40, 1 mM NaVO4, 50 mM NaF, 10 mM Na4P2O7, and protease
inhibitor cocktail [Roche]) and centrifuged at 26,000 g for 30 min. Postnuclear
supernatants were submitted to electrophoresis on 4%–12% gradient
SDS-PAGE gels, transferred to a nitrocellulose membrane, and immunoblot-
ted. Membranes were stripped in 0.1 M Glycine buffer (pH 2.3) in case of
reblotting for actin level control, Membranes were revealed with SuperSignal
West Pico Solution (Thermos Scientific; Rockford; IL).
Transmission Electron Microscopy
Cells were harvested and fixed in 2% formaldehyde and 1.5% glutaraldehyde
in 0.2 M sodium phosphate buffer (pH 7.4) at room temperature for 2 hr. Cells
were then washed once in sodium phosphate buffer and prepared for epon
sectioning. After ultramicrotome sectioning, sections were analyzed with a
Philips CM10 transmission electron microscope (Philips, Eindhoven,
Netherlands).
Flow Cytometry and Confocal Immunofluorescence
After isolation or differentiation, surface staining of primary cells (monocytes,
MDDCs, MyDCs and autologous CD4+ T cells) were performed at 4C for
30 min with mAbs from BD and directed against the following molecules:
CD1a, CD3, CD4, CD8, CD14, CD19, CD45Ro, CD69, CD83, CD86, DC-SIGN,
and HLA-DR. The following other mAbs from Miltenyi Biotec were used for
MyDC cell surface staining: anti-CD1c, anti-CD11c, anti-CD123, and anti-
CD303. Gag p24 expression was measured on permeabilized cells with anti-
Gagp24 (FITC-coupled) mAb (KC57, Coulter). Isotype-matched mAbs were
used as negative controls. Samples were analyzed by flow cytometry with a
FacsCalibur (Becton Dickinson) and data processed with FlowJo software.
For immunofluorescence, cells were left to adhere on poly-L-lysine-treated
glass coverslips for 60 min at 37C. Cells were then fixed, permeabilized,
and stained with indicated antibodies and then stained with fluorescently
labeled secondary antibodies from Jackson ImmunoResearch Laboratories
(West Grove, PA). Gag staining was done with anti-Gagp24 KC57-FITC
mAb. Confocal microscopy analysis was carried out on a Zeiss LSM510Meta
with a 633 objective. Z series of optical sections were performed at 0.5–1 mm
increments for qualitative analysis. Green, red, and far-red fluorescences were
acquired sequentially. Quantifications of LC3+ puncta and colocalization
events were performed with ImageJ Software (NIH) and analyzed with Excel
software (Microsoft).
Transfer Assay
After 8 hr of HIV-1 treatment, 105 of iDCs were replated in 96-round well plates
(Falcon; BD) in 100 ml final volume of IMDM and mixed with 105 autologous
CD4+ T cells previously treated with 2 mg/ml indinavir (Merck). Cells were left
in contact for coculture for 24–36 hr and then processed for FACS analysis
of intracellular HIV-1 Gag content in CD3+ T cells. Transfer of infection with
HIV-Luc/JRFL was performed as described previously (Wang et al., 2007).
TLR Stimulation
A total of 105 iDCs transfected with siRNA oligos or challenged with 200 ng p24
HIV-1 for 8 hr were stimulated with the Human TLR1-9 Agonist kit (InvivoGen,
San Diego, CA). TLR ligands:Pam3CSK4 (1 mg/ml), HKLM (108 cells/ml),
Poly(I:C) (2.5 mg/ml), LPS (200 ng/ml), Flagellin (1 mg/ml), FSL1 (1 mg/ml),
Imiquimod (1 mg/ml), ssRNA40 (1 mg/ml), and ODN2006 (5 mM) were incubated
with cells for 20 hr. BrefeldinA (10 mg/ml) was added upon 1 hr of TLR stimu-
lation. Cells were then fixed in 2% paraformaldehyde and intracellular cytokine
FACS was done.
Antigen Presentation
ELISPOT assays and Intracellular cytokine FACS on HS clone responses were
adapted from Moris et al. (2006). In brief, for ELISPOT assays, iDCs were
exposed for 4 hr to HIV-Mn/AT2 (100 ng/mL). Stimulator cells were then cocul-
tured for at least 24–36 hr with CD4+ T cell clones. IFN-g production was
measured in an enzyme-linked immunosorbent spot (ELISPOT) assay asdescribed (Buseyne et al., 2001; Moris et al., 2006) with a MABTECH IFN-g
ELISPOT assay kit (MABTECH, Sweden). As a positive control, stimulators
were incubated with cognate peptides (0.5 mg/ml) before addition of CD4+
clones. When stated, rapamycin (10 mg/ml), 3-methyladenine (1 mM), or chlo-
roquine (20 mg/ml) was added to stimulator cells 2 hr prior to viral exposure.
Statistical Analysis
Significant differences between groups were calculated with the Student’s
t test. p values < 0.05 were considered significant andmarked with an asterisk.
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